BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Original research on the business of biotech
We occasionally publish primary-source analysis: clinical trials, SEC filings, hedge fund positioning. See what we've written.
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Fairmount Funds Management LLC Apogee Therapeutics, Inc. (APGE) | 10.0% 13D/A [SEC] |
Redmile Group ABSCI CORP (ABSI) | 5.4% -1.1 13D/A [SEC] |
Baker Brothers Advisors Celcuity Inc. (CELC)
Investment
Other | 20.0% +1.1 13D/A [SEC] Baker Brothers Advisors, on behalf of its funds, notified Celcuity Inc. to increase the beneficial ownership limitation from 4.99% to 19.99% for prefunded warrants to purchase common stock held by 667 and Life Sciences. This change, effective May 20, 2026, allows the Reporting Persons to be deemed to beneficially own up to 19.99% of the outstanding Common Stock for investment purposes, without acquiring additional securities at this time. |
RA Capital Management Acrivon Therapeutics, Inc. (ACRV) | 21.6% 13D/A [SEC] |
RA Capital Management SAB BIOTHERAPEUTICS INC (SABS)
Financing
Warrants | 9.9% 13D/A [SEC] Agreements · RA Capital Management holds Pre-Funded Warrants with an exercise price of $0.0001 per share, immediately exercisable, and no expiration date. The warrants include a beneficial ownership blocker, preventing exercise if it would result in the fund owning more than 9.99% of the outstanding common stock. |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.